Company at a Glance
Biop Medical is an Israeli medical device startup, which has developed an innovative technology for the identification of cancerous cells in epithelium tissues. The technology is a platform technology, which will be implemented in a number of devices for cancer screening and diagnosis, beginning with cervical cancer.
Cervical cancer is the second most common cancer among women worldwide.
Biop’s real-time screening tool offers standard colposcope capabilities with state-of-the-art, enhanced features. The novel device combines advanced, high-resolution optics with integrated micro and macro cameras and other optical elements to produce highly sensitive optical signatures for automatic identification of suspicious areas and quantification of the cancer stage. The collected data is combined and analyzed using Biop’s proprietary algorithm.
Preliminary commercialization of Biop’s proprietary transducer will replace current colposcopy and other existing cervical screening technologies.
The Advantages of our Technology:
- Enables diagnosis of cancer and pre-cancerous tissues
- Automatically scans entire cervix for point-of-care diagnosis
- Generates a real-time map of the cervix for accurate biopsy, when necessary
- Eliminates dependency on operator proficiency due to software analysis
- Reduces the wait time (and associated anxiety) between testing and diagnosis
- Generates data sets for “big data”
Technology & Product(s)
Biop Medical’s patented technology combines advanced, high-resolution optics with integrated micro and macro cameras and additional optical elements to produce highly sensitive optical signatures for automatic identification of suspicious areas and quantification of cancer stage.
The collected data is combined and analyzed using Biop’s proprietary algorithm.
Preliminary commercialization of Biop’s proprietary transducer will offer a standard colposcope with enhanced features replacing current colposcopy technologies, offering a diagnostic aid for targeted biopsies.
The system generates a colored imaging map of the cervix in which suspected areas are highlighted, guiding operators to the lesions for biopsy. Biop’s real-time screening tool assesses and grades the lesions, saving the parameters in the patient’s EMR for monitoring.
Results of its proof of concept device have confirmed the advantages of the Biop approach in the ex- vivo and in- vivo studies performed. Testing has shown 86% accuracy in diagnosis.
Cervical cancer is the 4th most common cancer amongst women worldwide, and the 2nd most common cancer in women in the developing world. The Western world has an expensive and time-consuming screening process, which minimizes deaths, however the developing world suffers from 85% of the global burden of cervical cancer deaths (WHO, 2015).
Biop Medical’s revolutionary system will enable point of care diagnosis of cervical cancer in both the developed and developing world, decreasing healthcare costs, shortening diagnosis timeline and improving overall identification of this deadly disease.
Future developments will focus on additional epithelial based cancers.
Objectives: Seeking potential strategic partners and investors in order to advance to the commercialization stage
Target businesses: Strategic partners, hospitals, Distributors, Venture Capital, Investors
Target Countries: Germany, UK, France, Italy, Holland , USA, Canada, China